These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22348185)

  • 1. Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia.
    Khalafallah A; Rahman Z; Ogden K; Hannan T
    Mediterr J Hematol Infect Dis; 2012; 4(1):e2012003. PubMed ID: 22348185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon.
    Noun P; Inati A; Raffoul R; Younes JA; Mardini J; Khalife H
    Ann Hematol; 2022 May; 101(5):991-997. PubMed ID: 35278100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.
    Kim YK; Lee SS; Jeong SH; Ahn JS; Yang DH; Lee JJ; Kim HJ
    Blood Res; 2015 Mar; 50(1):19-25. PubMed ID: 25830126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.
    Cheng G
    Ther Adv Hematol; 2012 Jun; 3(3):155-64. PubMed ID: 23556122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review.
    Ulutaş F; Ök ZD; Uğur K; Çobankara V
    Mediterr J Rheumatol; 2022 Dec; 33(4):444-448. PubMed ID: 37034371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
    Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
    Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul.
    Dogan EE; Turan Erkek E; Elverdi T; Celik Kamaci S; Ciftci U; Demirel N; Aydin D; Eren R
    Indian J Hematol Blood Transfus; 2022 Apr; 38(2):327-332. PubMed ID: 35496971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Diagnosis and Treatments for Immune Thrombocytopenia.
    Nomura S
    Clin Med Insights Blood Disord; 2016; 9():15-22. PubMed ID: 27441004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.